{"nctId":"NCT02337738","briefTitle":"A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants","startDateStruct":{"date":"2015-01-27","type":"ACTUAL"},"conditions":["Parkinson's Disease"],"count":404,"armGroups":[{"label":"TVP-1012 1mg","type":"EXPERIMENTAL","interventionNames":["Drug: TVP-1012 1mg"]},{"label":"TVP-1012 0.5mg","type":"EXPERIMENTAL","interventionNames":["Drug: TVP-1012 0.5mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"TVP-1012 1mg","otherNames":[]},{"name":"TVP-1012 0.5mg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.\n* The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.\n* The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.\n* The participant has Modified Hoehn \\& Yahr stage 2 to 4 (in the \"Off\" state) at the start of the run-in period.\n* The participant has wearing off phenomenon and has been continuously receiving a levodopa combination drug for \\>= 6 months prior to the start of the run-in period.\n* The participant has been receiving a levodopa combination drug with a stable dose regimen (dosing frequency, at least 3 times a day) since the start of the run-in period.\n* For participants receiving eantacapone concomitantly,the participant has been receiving entacapone with a stable dose regimen from the start of the run-in period.\n* For participants receiving a dopamine agonist, anticholinergic drug, amantadine, droxidopa, istradefylline, or zonisamide concomitantly, the participant has been receiving those drugs with a stable dose regimen since 14 days prior to the start of the run-in period.\n* The participant is an outpatient of either sex aged \\>= 30 and \\< 80 years at the time of consent.\n* A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.\n* The participant has completed patient diary for at least 4 of the 7 days preceding the study visit at the end of the run-in period.\n* The participant has mean daily off-time of \\>= 2.5 hours at the end of the run-in period\n\nExclusion Criteria:\n\n* The participant has received any investigational medication within 90 days prior to the start of the run-in period.\n* The participant has received TVP-1012 in the past.\n* The participant is a study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.\n* Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.\n* The participant has unstable systemic disease.\n* The participant has severe dyskinesia.\n* The participant has Mini-Mental State Examination (MMSE) score of \\<= 24 at the start of the run-in period.\n* The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease\n* The participant has major depression or severe depression, or any other clinically significant psychiatric disease.\n* The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.\n* The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).\n* The participant has a history or concurrent of drug abuse or alcohol dependence.\n* The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).\n* The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period.\n* The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.\n* The participant has received single agent of levodopa, any psychoneurotic agent or antiemetic medication of dopamine antagonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for \\>= 14 days prior to the start of the run-in period may be included in the study.\n* The participant is required to take any of the prohibited concomitant medications or treatments.\n* If female, the participant is pregnant or lactating or intending to become pregnant during, or within 1 month after the last administration of study medication in this study; or intending to donate ova during such time period.\n* The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.\n* The participant has clinically significant or unstable brain or cardiovascular disease, such as:\n\n  * clinically significant arrhythmia or cardiac valvulopathy,\n  * heart failure of NYHA Class II or higher,\n  * concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,\n  * concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the stat of the run-in period,\n  * severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),\n  * clinically significant orthostatic hypotension (including those with diastolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position), or\n  * a history of syncope due to hypotension within 2 years prior to the stat of the run-in period.\n* The participant is required surgery or hospitalization for surgery during the study period.\n* Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.\n* The participant has acquired immunodeficiency syndrome (AIDS) \\[including human immunodeficiency virus (HIV) carrier\\], or hepatitis \\[including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive\\]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.\n* The participant has laboratory data meeting any of the following at the start of the run-in period:\n\n  * Creatinine \\>= 2 x upper limit of normal (ULN)\n  * Total bilirubin \\>= 2 x ULN\n  * ALT or AST \\>= 1.5 x ULN\n  * ALP \\>= 3 x ULN\n* The participant has received any of the prohibited concomitant medications or treatments during the run-in period.\n* The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason.","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Mean Daily OFF-time During Treatment Period","description":"Reported change from baseline during treatment period which was calculated as follows: Mean for a total of 21 days, consisting of three separate 7-day periods preceding the visits at Week 6, 14 and 26 of the treatment period - Mean for the 7 days preceding the visit at the end of the run-in period. Off-time refers to times when levodopa is not working well, causing worsening symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.51","spread":"0.167"},{"groupId":"OG001","value":"-1.11","spread":"0.174"},{"groupId":"OG002","value":"-1.35","spread":"0.177"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 26 (LOCF) in Mean Daily OFF-time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.207"},{"groupId":"OG001","value":"-0.99","spread":"0.217"},{"groupId":"OG002","value":"-1.40","spread":"0.220"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II Total Score","description":"MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part II Total Score was 0-52, with higher scores reflecting greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.408"},{"groupId":"OG001","value":"-0.30","spread":"0.421"},{"groupId":"OG002","value":"-0.30","spread":"0.431"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in MDS-UPDRS Part III Total Score","description":"MDS-UPDRS retains the four-scale structure with a reorganization of the various subscale; (Part I; 13 items) non-motor experiences of daily living, (Part II; 13) motor experiences of daily living, (Part III; 34) motor examination, and (Part IV; 6) motor complications. Each items had 0-4 ratings, where 0 (normal) to 4 (severe) and score for each was summed to calculate the total scores. The scale range for Part III Total Score was 0-136, with higher scores reflecting greater severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.50","spread":"0.605"},{"groupId":"OG001","value":"-5.24","spread":"0.623"},{"groupId":"OG002","value":"-5.65","spread":"0.637"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Score","description":"PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.84","spread":"0.809"},{"groupId":"OG001","value":"0.33","spread":"0.829"},{"groupId":"OG002","value":"-1.00","spread":"0.857"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Parkinson's Disease Questionnaire-39 (PDQ-39) Each Domain Score","description":"PDQ-39 is a self-administered questionnaire. PDQ-39 comprises of 39 questions, relating to eight key areas (Mobility, Activities of Daily Living, Emotional Well-being, Stigma, Social Support, Cognitions, Communication, and Bodily Discomfort) of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.36","spread":"1.515"},{"groupId":"OG001","value":"-0.64","spread":"1.552"},{"groupId":"OG002","value":"-2.80","spread":"1.605"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.42","spread":"1.348"},{"groupId":"OG001","value":"-1.28","spread":"1.382"},{"groupId":"OG002","value":"-3.72","spread":"1.429"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"1.295"},{"groupId":"OG001","value":"-0.01","spread":"1.329"},{"groupId":"OG002","value":"-0.36","spread":"1.372"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.14","spread":"1.161"},{"groupId":"OG001","value":"-3.28","spread":"1.190"},{"groupId":"OG002","value":"-2.90","spread":"1.229"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.46","spread":"1.043"},{"groupId":"OG001","value":"0.60","spread":"1.072"},{"groupId":"OG002","value":"1.38","spread":"1.104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"1.219"},{"groupId":"OG001","value":"3.15","spread":"1.252"},{"groupId":"OG002","value":"0.69","spread":"1.291"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.66","spread":"1.107"},{"groupId":"OG001","value":"1.59","spread":"1.136"},{"groupId":"OG002","value":"2.26","spread":"1.172"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.36","spread":"1.367"},{"groupId":"OG001","value":"2.36","spread":"1.401"},{"groupId":"OG002","value":"-0.92","spread":"1.449"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experience at Least One Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"93","spread":null},{"groupId":"OG002","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Markedly Abnormal Vital Signs Values","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAE Related to Body Weight (Weight Decreased)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAE Related to Electrocardiograms (ECG) (Sinus Bradycardia)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With TEAE Related to Clinical Laboratory Tests","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":141},"commonTop":["Nasopharyngitis","Dyskinesia","Fall","Contusion"]}}}